Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005.
BACKGROUND
Between 1992 and 2001 the UK general practice incidence of post-herpetic neuralgia and trigeminal neuralgia declined, whilst the incidence of painful diabetic neuropathy increased. The most common first line treatments were compound analgesics. As therapeutic options have subsequently changed, this study presents updated data on incidence and prescribing patterns in neuropathic pain.


METHODS
A descriptive analysis of the epidemiology and prescription treatment at diagnosis of incident post-herpetic neuralgia (n = 1,923); trigeminal neuralgia (1,862); phantom limb pain (57) and painful diabetic neuropathy (1,444) using computerised UK general practice records (THIN): May 2002 to July 2005.


RESULTS
Primary care incidences per 100,000 person years observation of 28 (95% confidence interval (CI) 27-30) for post-herpetic neuralgia, 27 (95%CI 26-29) for trigeminal neuralgia, 0.8 (95%CI 0.6-1.1) for phantom limb pain and 21 (95%CI 20-22) for painful diabetic neuropathy are reported. The most common initial treatments were tricyclic antidepressants (post-herpetic neuralgia) or antiepileptics (trigeminal neuralgia and painful diabetic neuropathy) and opioid analgesics (phantom limb pain). The mean number of changes before a stable drug regimen was 1.2 to 1.5 for trigeminal neuralgia, painful diabetic neuropathy and post-herpetic neuralgia, and 2.4 for phantom limb pain.


CONCLUSIONS
The incidence of phantom limb pain and post-herpetic neuralgia are decreasing whilst painful diabetic neuropathy plateaued and trigeminal neuralgia remained constant. Despite more frequent use of antidepressants and antiepileptics for first line treatment, as opposed to conventional non-opioid analgesics, changes to therapy are common before a stable regimen is reached.
Hall
Gillian C
GC
Grimsdyke House, London, UK. gillian_hall@gchall.demon.co.uk
Carroll
Dawn
D
McQuay
Henry J
HJ
D000700:Analgesics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009437:Neuralgia; D051474:Neuralgia, Postherpetic / Q000188:drug therapy / Q000453:epidemiology*; D019370:Observation; D010591:Phantom Limb / Q000188:drug therapy / Q000453:epidemiology*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011320:Primary Health Care; D014277:Trigeminal Neuralgia / Q000188:drug therapy / Q000453:epidemiology*; D006113:United Kingdom / Q000453:epidemiology
D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents